https://www.selleckchem.com/pr....oducts/ulixertinib-b
To evaluate predictive clinical and histopathological risk factors for bladder cancer recurrence in patients who underwent nephroureterectomy for primary upper urinary tract transitional cell carcinoma (TCC). Data of 111 patients, who were diagnosed with upper urinary tract TCC and underwent nephroureterectomy were reviewed A total of 65 patients were included in the study, after excluding 34 patients. Results Bladder cancer recurrence developed in 20 (30.7%) of the 65 patients under evaluation. The recurrence-free
Like
Comment
Share
